Two markers help predict head and neck cancer prognosis

HPV circulating tumor DNA and MRI/PET imaging markers predicted which tumors would respond to chemoradiation as early as two weeks into treatment.

5:00 AM

Author | Nicole Fawcett

blue xray throat tumor lump with lab note written in blue with yellow overlay on bottom right
Getty Images

A new study from the University of Michigan Health Rogel Cancer Center finds circulating tumor DNA, or ctDNA, levels can predict as early as two weeks after starting treatment which patients are likely to have good outcomes.

At the same time, specialized MRI and PET scans two weeks after starting chemoradiation also correlated with outcomes.

"Rates of throat cancer have steadily increased in recent years, driven by HPV infections, fueling the need for biomarkers to help guide treatment decisions, especially for locally advanced disease," said senior study author J. Chad Brenner, Ph.D., associate professor of otolaryngology at Michigan Medicine.

"Quantitative imaging of metabolism, local blood volume density and cell density from PET and MRI scans have shown both prognostic value in predicting treatment outcome as well as utility in selecting patients for additional focal radiation treatment," said study author Yue Cao, Ph.D., professor of radiation oncology and radiology at Michigan Medicine.

The researchers conducted a randomized trial of patients with stage 3 oropharyngeal squamous cell carcinoma. In total, 93 patients had imaging and 34 also had blood tests before starting chemoradiation and again at two, four and seven weeks after treatment.

The study found that HPV ctDNA clearance at two weeks, but not at four weeks, predicted outcomes. The metabolism, local blood density and cell density before radiation therapy or at two weeks after starting treatment predicted outcomes as well. These early predictor biomarkers could help determine which patients need more aggressive treatment. A larger study is needed.

Funding for this work was from National Cancer Institute grants U01CA183848, R01CA184153 and P30CA046592.

The University of Michigan has filed a patent on the HPV ctDNA assay that was used in this paper.

Paper cited: "Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma," Clinical Cancer Research. DOI: 10.1158/1078-0432.CCR-21-2338


More Articles About: Lab Notes Head and Neck Cancer Cancer Research All Research Topics Cancer: Cancer Types
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories stained glass green blue purple orange pink
Health Lab
Massive study identifies new biomarkers for renal cancer subtypes, improving diagnosis and—eventually—treatment
A study led by University of Michigan Health Rogel Cancer Center researchers identifies novel biomarkers in renal cell carcinomas.
woman holding face looking stressed on white couch in white shirt dark blue pants
Health Lab
Health costs top older adults’ list of concerns for people their age, poll finds
People over 50 of all backgrounds say they’re most concerned about various kinds of health costs affecting people their age, including insurance, prescriptions, medical care, dental care and home or longterm care.
kidneys blue yellow
Health Lab
Why personalized medicine is important in rare kidney disease
Building a comprehensive human kidney cell and tissue catalog could help develop more treatments for kidney disease.
Scientific illustration of gliobastoma cells in the brain
Health Lab
Path forward for glioblastoma treatment
Experts in brain cancer outline current discoveries and offer a path of hope for glioblastoma treatment
Xray of a stem cell in a mouse brain.
Health Lab
Stem cells improve memory, reduce inflammation in Alzheimer’s mouse brains
Researchers improved memory and reduced neuroinflammation in a mouse model of Alzheimer’s Disease, suggesting another avenue for potential treatment.
Illustration of hand holding list, with pill bottle in opposite and and small pic of doctor talking to patient
Health Lab
New urine-based test detects high grade prostate cancer, helping men avoid unnecessary biopsies
A new urine-based test addresses a major problem in prostate cancer: how to separate the slow growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment.